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Abstract Acute treatment of men-
strual migraine (MM) attacks is
often incomplete and unsatisfacto-
ry, and perimenstrual prophylaxis
with triptans, oestrogen supple-
mentation or naproxen sodium may
be needed for decreasing frequen-
cy and severity of the attack. In
this pilot, open-label, non-ran-
domised, parallel group study we
evaluated, in 38 women with a his-
tory of MM, the efficacy of frova-
triptan (n=14) 2.5 mg per os or
transdermal oestrogens (n=10) 25
μg or naproxen sodium (n=14) 500
mg per os once-daily for the short-
term prevention of MM. All treat-
ments were administered in the
morning for 6 days, beginning 2
days before the expected onset of
menstrual headache. All women
were asked to fill in a diary card,
in the absence of (baseline) and
under treatment, in order to score
headache severity. All women
reported at least one episode of
MM at baseline. During treatment
all patients taking transdermal
oestrogens or naproxen sodium
and 13 out of the 14 patients
(93%) taking frovatriptan had at
least one migraine attack
(p=0.424). Daily incidence of
migraine was significantly
(p=0.045) lower under frovatriptan
than under transdermal oestrogens
or NS. At baseline, the overall
median score of headache severity
was 4.6, 4.2 and 4.3 in the group
subsequently treated with frova-
triptan, transdermal oestrogens and
naproxen sodium, respectively
(p=0.819). During treatment the
median score was significantly
lower under frovatriptan (2.5) than
under transdermal oestrogens (3.0)
and naproxen sodium (3.9,
p=0.049). This was evident also
for each single day of observation
(p=0.016). Among treatments dif-
ferences were particularly evident
for the subgroup of patients with
true MM (n=22) and for frovatrip-
tan vs. naproxen sodium. This
study suggests that short-term pro-
phylaxis of MM with frovatriptan
may be more effective than that
based on transdermal oestrogens or
naproxen sodium. 
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Introduction
According to recent statistics migraine affects 15%–20%
of women, being more frequent in this population than in
men [1,2]. The most common form of migraine in women
is menstrual migraine (MM) [3], a migraine without aura
occurring regularly in close relationship with the onset of
menstruation (between 2 days before and up to 3 days
after the onset of bleeding) [4]. There are two acknowl-
edged types of MM: the so-called menstrually related
migraine, characterised by attacks occurring also at other
times of the cycle, and the pure or true MM, starting
exclusively between the days immediately before and
immediately after the first day of the menstrual cycle
[3,4].
The origin of MM is to be ascribed to the sudden fall
of serum oestrogen levels immediately preceding menses,
triggering abnormal neurotransmitter and neurohormonal
responses or abnormal release of prostaglandins [3-6].
Effective acute therapy is the mainstay of management
for menstrual attacks, although there is much evidence
that attacks linked to menstruation may not respond to the
usual antimigraine medications [7,8]. In this case peri-
menstrual prophylaxis with naproxen sodium, oestradiol
supplementation or triptans has been shown to be effective
in decreasing attack frequency and severity [9-14]. Among
the various triptans effectively employed in MM, frova-
triptan is a second-generation triptan showing high selec-
tivity for cerebral vasculature, long elimination half-life
and high persistence of therapeutic action and may ensure
an effective preventive treatment of MM [11,15], with a
better safety profile than other triptans [16].
In the present study the efficacy of frovatriptan in the
prevention of MM attacks has been compared with that of
other treatments (transdermal oestrogens and naproxen
sodium) commonly and widely employed for this purpose.
Methods
Patients
Female subjects, aged 18 years or more, with at least a 12-month
documented history of menstrual headaches occurring from 2
days before to the first 3 days of menstruation in at least two out
of three menstrual cycles, as defined by Headache Classification
Committee of the International Headache Society [4], were
enrolled. Only women with regular menstrual cycles in the previ-
ous 6 months [17] and able to predict the onset period of men-
strual headache could be enrolled in the study. Exclusion criteria
were: (a) occurrence of more than three migraine attacks per
month not classified as MM attacks, (b) a history of cardiovascu-
lar or cerebrovascular disease, renal or liver insufficiency or
other clinically relevant diseases, (c) moderate or severe arterial
hypertension or mild uncontrolled arterial hypertension, (d) more
than 15 headache days per month, exclusive of migraine
headache, (e) known hypersensitivity to frovatriptan, (f) treat-
ment with ergot medications, other 5-HT agonists or MAO
inhibitors at the time of enrolment, (g) any change in the type or
dose of any prophylactic migraine medication in the 2 months
prior to screening or any anticipated change during study partic-
ipation.
Written informed consent was obtained from all patients prior
to their inclusion into the study. 
Study design
This was a pilot, open-label, non-randomised, parallel group
study. Eligible patients were treated with frovatriptan 2.5 mg per
os or transdermal oestrogen 25 μg or naproxen sodium 500 mg
per os once-daily. All treatments were administered in the morn-
ing for 6 days, beginning 2 days before the expected onset of the
menstrual headache (considering day 0 as when bleeding started).
Assessment of efficacy was based on a patient’s diary card where
intensity of migraine had to be reported on a daily basis. The
diary had to be completed by patients on two occasions: the first
in the absence of treatment (control or baseline) and the second
during treatment with one of the three drugs. Headache severity
was rated using a 10-point anchored scale where 0 is no headache
and 10 is severe headache. No escape or rescue medication was
allowed during the study.
Data analysis
As this was a pilot study, no formal sample size estimation was
carried out at the time of study planning. Drug efficacy was
assessed by calculating the percentage of patients with MM (inci-
dence of the disease) and the score of headache intensity or
severity from 2 days before to 3 days after menses. Study vari-
ables were also computed by day of treatment, separately for the
baseline and treatment period. Analysis for subgroups of patients
with true MM and menstrually related migraine was also per-
formed.
Incidence of MM was compared among treatments by the
non-parametric Kruskal–Wallis test. Given the non-normal distri-
bution of headache severity score, as verified by the
Shapiro–Wilk test, the score was summarised using median val-
ues and among-treatments comparison was done by the non-para-
metric Kruskal–Wallis test. An analysis of variance for repeated
measures corrected for multiple comparisons was used for confir-





Demographic and clinical data at entry
A total of 38 patients were enrolled, of whom 14 (37%)
treated with frovatriptan, 10 (26%) with transdermal oestro-
gens and 14 (37%) with naproxen sodium. All patients had
a previous diagnosis of MM, the most common form being
true MM (58% of patients). Most women had a positive
family history for migraine (53%) and were previously tak-
ing antimigraine drugs (55%). At baseline, distribution of all
demographic and clinical data was not significantly different
among the three treatment groups, though some differences
were observed in the prevalence of subtypes of MM and in
the use of drugs (Table 1).
Incidence of menstrual migraine
In the absence of treatment (baseline) all patients had at least
one MM attack. Typically, incidence of migraine attacks
was low before menses and rapidly increased after menstru-
ation (Fig. 1). No statistically significant difference
(p=0.823) was observed in the incidence of migraine at
baseline among the three study treatment groups.
During treatment all patients taking transdermal oestro-
gens or naproxen sodium and 13 out of the 14 patients
(93%) taking frovatriptan had at least one migraine attack
(p=0.424 among treatments). Incidence of migraine during
each day of observation was significantly (p=0.045) lower
under frovatriptan than under transdermal oestrogens or
naproxen sodium (Fig. 1), this being particularly true for the
subgroup of patients with true MM (average prevalence
60% under frovatriptan, 79% under oestrogens and 78%
under naproxen sodium).
Fig. 1 Percentage (%) of patients with MM at baseline (panel A) and
during treatment (panel B), in the group assigned to treatment with
frovatriptan 2.5 mg od (open bars, n=14), transdermal oestrogen 25
μg (striped bars, n=10) or naproxen sodium 500 mg od (full bars,
n=14). Data are shown for the two days preceding (–2 and –1) and
the 3 days following menses (1, 2 and 3), and for the day when
bleeding started (0). p refers to interaction between treatment and
time
Table 1 Demographic and clinical data of study population at inclusion (n=34)
Frovatriptan (n=14) Transdermal oestrogens (n=10) Naproxen sodium (n=14)
Age (years, mean±SD) 32±8 29±4 34±8
Subtypes of MM (n, %)
True MM 8 (57) 4 (40) 10 (71)
Menstrually-related migraine 6 (43) 6 (60) 4 (29)
Positive family history for migraine (n, %) 7 (52) 6 (60) 7 (53)
Previous treatments for migraine (n, %)
Other triptans 4 (29) 5 (50) 3 (21)
Prophylaxis with calcium antagonists 2 (14) - –
Prophylaxis with beta-blockers 1 (7) - –
Oestroprogestins – 4 (40) 2 (14)
Concomitant treatments (n, %) – 3 (30)a 1 (7)b
aLansoprazol; bantipsoriatic treatment
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Severity of menstrual migraine
Median scores of headache severity by type of drug at base-
line and during treatment are shown in Figure 2. At baseline,
headache severity reached its apex between days 0 and 1
with a non-significantly different trend among the three
treatment groups (p=0.277), the overall median score being
4.6 in the group subsequently treated with frovatriptan, 4.2
in that treated with transdermal oestrogens and 4.3 in that
treated with naproxen sodium (p=0.819).
During treatment the median score was significantly
lower under frovatriptan than under transdermal oestrogens
and naproxen sodium (2.5 vs. 3.0 and 3.9, respectively,
p=0.049). This was evident also for each single day of
observation (Fig. 2, among treatments difference p=0.016)
and in particular for frovatriptan vs. naproxen sodium.
As shown in Figure 3, the superiority of frovatriptan
vs. naproxen sodium, in terms of attenuation of headache
severity, was evident only for the subgroup of patients
with true MM (p=0.047 multiple comparisons test).
Discussion
In our study perimenstrual prophylaxis with frovatriptan,
transdermal oestrogens and naproxen sodium was carried
out in women with known MM, according to an open-label,
non-randomised, parallel group design. During one peri-
menstrual period of observation, frovatriptan proved to be
superior to transdermal oestrogens and naproxen sodium in
reducing the incidence of migraine attacks and their severi-
ty, with respect to a previous wash-out period, particularly in
the subgroup of women with true MM.
This is the first evidence of a direct comparison of the
efficacy of triptans, oestradiol and non-steroidal anti-inflam-
matory drugs as a prophylactic measure for MM attacks,
showing the superiority of triptans over other drugs usually
employed for the prevention of this type of migraine.
Previous studies have separately assessed the efficacy of
these three classes of drugs for prevention of MM. In a small
open-label study involving 20 women, sumatriptan given at
25 mg 3 times per day reduced the incidence of headache by
50% as well as its severity, as compared to baseline [13]. In
a larger (59 women) open-label study, naratriptan 1 mg given
2 times per day 2 days before menstruation and for the fol-
lowing 6 days for a total of 3 months decreased the frequen-
Fig. 2 Median score of headache severity at baseline (panel A) and
during treatment (panel B), in the group assigned to treatment with
frovatriptan 2.5 mg od (continuous line, n=14), transdermal oestro-
gen 25 μg (dashed line, n=10) or naproxen sodium 500 mg od (dot-
ted line, n=14). Data are shown for the two days preceding (–2 and
–1) and the 3 days following menses (1, 2 and 3), and for the day
when bleeding started (0). p refers to interaction between treatment
and time
Fig. 3 Median score of headache severity during treatment in the
patients with true MM treated with frovatriptan 2.5 mg od (contin-
uous line) or naproxen sodium 500 mg od (dotted line). Data are
shown for the two days preceding (–2 and –1) and the 3 days fol-
lowing menses (1, 2 and 3), and for the day when bleeding started
(0). p refers to interaction between treatment and time
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cy of migraine attacks by nearly two over the course of 3
months as compared to placebo [14]. In a double-blind study
2.5 mg of naratriptan 2 times per day, but not 1 mg, was
effective in reducing the incidence of headache [12].
Efficacy of frovatriptan 2.5 mg once or twice daily in the
short-term prevention of MM was tested vs. placebo in a dou-
ble-blind study where treatment was commenced 2 days
before anticipated MM, preceded by a loading dose of 5 or
10 mg [11]. In this study women taking frovatriptan 2.5 mg
once-daily for 3 perimenstrual periods had an incidence of
MM of 52% vs. 67% under placebo, the incidence being 41%
under frovatriptan 2.5 mg twice-daily. Significant reductions
were also observed in headache severity in the group treated
with frovatriptan. In our study, incidence of headache after
treatment with frovatriptan was only marginally reduced as
compared to the control period, but the headache severity
was consistently blunted, significantly more than under
naproxen sodium or transdermal oestrogens. This is consis-
tent with results of previous studies based on short-term pre-
vention of MM with such treatments.
Indeed, even though use of oestrogens for prevention of
MM has been supported by the hypothesis that this condition
may be due to oestrogen withdrawal or fluctuations, stabilised
or prevented by oestrogen supplementation, use of oestradiol
patch at doses even higher than those used in our study (50 vs.
25 μg of our study) did not affect the incidence, duration and
severity of migraine attacks compared with placebo [18]. In a
double-blind, placebo-controlled study, short-term preventive
treatment with naproxen sodium, at doses higher than those
used in our study (550 mg twice daily vs. 500 mg once-daily
in our study) reduced the incidence of headache attacks by
33%, with a lesser headache intensity and duration in patients
receiving this drug as compared to placebo [19]. In our study
neither transdermal oestrogens nor naproxen sodium altered
the incidence of headache as compared to the control period.
They reduced the severity of headache but in a way consis-
tently and significantly less than frovatriptan.
Unfortunately, as mentioned above, the drug doses used
in our study were roughly half of those usually employed in
clinical trials assessing the efficacy of preventive treatment
of MM and thus the study results might have been underes-
timated. As a matter of fact it has been demonstrated that
patches containing 25 μg (the dose employed in our study)
or 50 μg of oestrogens may be poorly effective [20-22],
while this is not the case for doses of 100 μg [20], probably
because low doses of oestrogens do not allow the critical
threshold for their efficacy to be achieved [23]. Besides, use
of high-dose oestrogen supplementation may be dangerous,
increasing the risk of ischaemic stroke in high-risk women
[3]. Regarding naproxen, there are no studies evaluating its
efficacy in MM and we must acknowledge that a single 500-
mg daily dose may not be optimal for this indication. Also
frovatriptan was used at a suboptimal dose, as 5 mg/day is
usually considered the minimal effective dose [11], with
some efficacy being sometimes observed also at 2.5 mg/day.
This administration time scheduling and dosing was chosen
because we decided to follow the scheme usually applied by
doctors to their patients in our country, though we acknowl-
edge it is far from ideal and optimal.
Another limitation of our study is the limited sample
size, and the open-label, non-randomised, pilot study nature
of the design. The study was also based on only one peri-
menstrual period of observation under active drug treatment.
However, this is the first study comparing these three treat-
ments in women with MM. As this condition is often more
severe than other types of migraine and its response to acute
treatment is often less favourable than for other forms of
migraine [7-10], our study results strengthen the usefulness
of short-term prevention of this condition with triptans, pre-
viously reported by open-label and double-blind controlled
studies [11-14]. The relatively similar effect of frovatriptan
and transdermal oestrogens on severity of headache attacks
in the subgroup of women with true MM, and the hypothe-
sised possible interaction between serotonin synthesis and
oestrogen [24] in the genesis of MM, also suggests a poten-
tial benefit in the combination of these two drugs for pro-
phylaxis of this subtype of MM.
In conclusion, results of our study suggest that short-term
prophylaxis of MM with frovatriptan 2.5 mg/day given in the
perimenstrual period is more effective than that based on
transdermal oestrogens or naproxen sodium in terms of atten-
uation of headache severity, but not in the reduction of inci-
dence of migraine attacks. Further large double-blind, ran-
domised, placebo-controlled studies are needed to definitive-
ly prove the efficacy of frovatriptan vs. other standard prophy-
lactic treatment in this subpopulation of migrainous patients.
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